Stay updated with breaking news from Keynote b61. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma. ....